No Data
Dyadic International, Inc. Advances Alternative Proteins Business and Vaccine Development Ahead of J.P. Morgan Healthcare Conference
Express News | Dyadic Provides Business Update; Dyadic to Attend the 43Rd Annual J.P. Morgan Healthcare Conference
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Dyadic International Receives $3 Million Grant From Gates Foundation for Monoclonal Antibody Development Targeting RSV and Malaria
Express News | Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for Rsv and Malaria Using C1 Platform Technology
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
ceoram : @Jaguar8 sleeper and upcoming earning report. Had a short run until it hit a sell off from what I’m seeing. Would like your perspective.